期刊文献+

瑞舒伐他汀抑制血小板衍生生长因子诱导的血管平滑肌细胞的增殖和迁移 被引量:4

Rosuvastatin inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells
下载PDF
导出
摘要 目的:探讨瑞舒伐他汀对血管平滑肌细胞增殖和迁移的影响及其分子机制。方法:采用血小板衍生生长因子(PDGF)-BB预处理血管平滑肌细胞,观察其对血管平滑肌细胞的增殖和迁移的作用,以及对基质金属蛋白酶(MMP)2、MMP9的表达、ERK1/2和P38蛋白的磷酸化水平的影响。结果:血小板衍生生长因子(PDGF)-BB处理后,血管平滑肌细胞的增殖和迁移明显上调,并伴随着细胞去分化为增殖型表型。而瑞舒伐他汀能显著抑制PDGF-BB诱导的血管平滑肌细胞的增殖、迁移以及表型转变;瑞舒伐他汀可抑制PDGF-BB诱导的血管平滑肌细胞中基质金属蛋白酶(MMP)2、MMP9的表达,并下调ERK1/2和P38蛋白的磷酸化水平。结论:瑞舒伐他汀可能通过部分下调PDGF-BB诱导的MAPK信号通路活性及MMP2、MMP9的表达,从而抑制血管平滑肌细胞的异常增殖和迁移,提示瑞舒伐他汀对内膜增生相关的动脉粥样硬化和介入后再狭窄具有治疗作用。 Aim:To evalute the effect of rosuvastatin on the vascular smooth muscle proliferation and migration as well as the involved molecular mechanisms.Methods:Vascular smooth muscle was pretrea-ted with platelet-derived growth factor (PDGF)-BB.Then proliferation and migration of vascular smooth muscle cell,the protein expression of matrix metalloproteinase (MMP)2 and MMP9,as well as the phosphorylation levels of ERK1 /2 and P38 in vascular smooth muscle cells were observed.Results:This study showed that under the treatment of PDGF-BB,the proliferation and migration of vascular smooth muscle cell significantly increased,along with these cells differentiating into the proliferative phenotype. However,rosuvastatin significantly inhibited PDGF-BB-induced vascular smooth muscle cell prolifera-tion,migration,and the phenotypic change mentioned above.Further studies showed that rosuvastatin in-hibited PDGF-BB-induced the protein expression of matrix metalloproteinase (MMP)2 and MMP9,as well as the phosphorylation levels of ERK1 /2 and P38 in vascular smooth muscle cells.Conclusion:It suggested that rosuvastatin inhibited PDGF-BB-induced vascular smooth muscle cell proliferation and mi-gration,probably through downregulating the activity of MAPK signaling pathway and the protein expres-sion of MMP2 and MMP9 ,indicating that rosuvastatin may have therapeutic effects on atherosclerosis and restenosis after intervention,which are associated with intimal hyperplasia.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2013年第6期588-592,共5页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 广西壮族自治区科技厅基金项目(桂科攻1140003A-50)
关键词 瑞舒伐他汀 血管平滑肌细胞 血小板衍生生长因子 增殖 迁移 Rosuvastatin vascular smooth muscle cells platelet-derived growth factor prolif-eration migration
  • 相关文献

参考文献11

  • 1LACOLLEY P,REGNAULT A,NICOLETTI. The vascular smooth muscle cell in arterial pathology:a cell that can take on multiple roles[J].{H}Cardiovascular Research,2012,(02):194-204.
  • 2CHOII B,CHA B,YAGYU T. Sponge-derived acetylenic alcohols,petrosiols,inhibit proliferation and migration of platelet-derived growth factor (PDGF)-in-duced vascular smooth muscle cells[J].{H}Bioorganic and Medicinal Chemistry Letters,2013,(07):1804-1810.
  • 3MAHALWAR R,KHANNA D. Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular dis-orders[J].{H}EUROPEAN JOURNAL OF PHARMACOLOGY,2013,(1-3):57-62.
  • 4ZHU L,GUAN H,CUI C. Gastrodin inhibits cell proliferation in vascular smooth muscle cells and attenu-ates neointima formation in vivo[J].{H}International Journal of Molecular Medicine,2012,(05):1034-1040.
  • 5SIMON D. Inflammation and vascular injury:basic dis-covery to drug development[J].{H}CIRCULATION JOURNAL,2012,(08):1811-1818.
  • 6PARK E,LEE K,JUNG S. Compound K,an in-testinal metabolite of ginsenosides,inhibits PDGF-BB-in-duced VSMC proliferation and migration through G1arrest and attenuates neointimal hyperplasia after arterial injury[J].{H}ATHEROSCLEROSIS,2013,(01):53-60.
  • 7LEHTI K,ROSE N,VALAVAARA S. MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing[J].{H}Journal of Cell Science,2009,(Pt 1):126-135.
  • 8ZHAO Y,LV M,Lin H. ROCK1induces ERK nuclear translocation in PDGF-BB-stimulated migration of rat vascular smooth muscle cells[J].{H}IUBMB LIFE,2012,(02):194-202.
  • 9YANG J,LIN J,WENG S. Crude extract of Eu-phorbia formosana inhibits the migration and invasion of DU145 human prostate cancer cells:The role of matrix metalloproteinase-2/9 inhibition via the MAPK signaling pathway[J].Mol Med Rep,2013,(05):1403-1408.
  • 10NICHOLLS S,Uno K,KATAOKA Y. Clinical experi-ence with rosuvastatin in the management of hyperlipi-demia and the reduction of cardiovascular risk[J].Ex-pert Rev Cardiovasc Ther,2011,(11):1383-1390.

同被引文献21

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部